Balchem Corporation

Balchem Corporation

BCPCNYSE / NASDAQBasic MaterialsMid cap

$163.54-$2.00 (-1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$5.1B
P/E
32.8x
EV / EBITDA
20.3x
Revenue
$1.0B
Net margin
14.9%
ROCE
14.7%

+7.1% over the last year

Balchem Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-4.7%
3M
-9.0%
6M
+1.5%
1Y
+7.1%
5Y
-2.3%

52-week range

Day change -$2.00 (-1.2%) from $166 to $164 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BCPC, bought on each weekday since 2021.

News & filings

What Balchem filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 20.2% against a peer median of 7.2%.

Concerns (1)

  • Revenue grew 3.2% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

Read moreShow less

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

Sector
Basic Materials
Shares outstanding
32.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.1B
P/E
32.8x
P/B
4.0x
EV / EBITDA
20.3x
EV / Sales
5.0x
P/S
4.9x
52-week high
$183.26
52-week low
$147.36

Profitability

Operating margin
20.2%
Net margin
14.9%
EBITDA margin
24.6%
ROE
12.3%
ROCE
14.7%
ROA
9.2%
Asset turnover
0.62

Growth

Revenue
$1.0B
Revenue growth, 1Y
8.8%
Revenue CAGR, 3Y
3.2%
Net profit growth, 1Y
20.5%
Free cash flow
$173.1M

Solvency

Current ratio
2.07
Debt / Equity
0.14
Debt / Assets
0.11
CFO / Net profit
1.40
Cash / Market cap
1.5%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Balchem Corporation income statement flow, FY2025
Balchem Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$666.5M
RevenueGross profit$370.6M
Gross profitOperating expenses$161.3M
Gross profitOperating income$209.3M
Operating incomePretax income$199.0M
Operating incomeInterest and other expense$10.3M
Pretax incomeTax and other$44.2M
Pretax incomeNet income$154.8M

Revenue and net profit

Revenue grew 8.8% in FY2025; net profit is the dashed line.

Balchem Corporation revenue and net profit by fiscal year
Balchem Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$942.4M$105.4M
FY2023$922.4M$108.5M
FY2024$953.7M$128.5M
FY2025$1.0B$154.8M

Cash flows

FY2025: $216.6M from operations, $173.1M free after investment (dashed).

Balchem Corporation operating and free cash flow by fiscal year
Balchem Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$138.5M$88.6M
FY2023$183.8M$145.9M
FY2024$182.0M$146.3M
FY2025$216.6M$173.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.0B+8.8%1Y
EBITDA
$254.9M+10.4%1Y
Net profit
$154.8M+20.5%1Y
Cash from operations
$216.6M+19.0%1Y
Free cash flow
$173.1M+18.3%1Y
Revenue CAGR, 3Y
3.2%
Net profit CAGR, 3Y
13.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.0B$254.9M$154.8M$173.1M12.3%+8.8%+20.5%

Monthly returns

Month-by-month returns of BCPC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.7B
Liabilities$428.8M
Equity$1.3B
Paid-in capital$92.3M
Retained earnings$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Basic Materials companies placed by value, growth and quality; BCPC highlighted.

P/E against peers

BCPC trades at 32.8x earnings against a peer median of 39.0x (a 16% discount).

Not shown (no positive earnings and no EV / Sales): Celanese Corporation, The Chemours Company.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Balchem CorporationBCPCthis companyP/E ↓ discount$5.1B32.8x4.0x12.3%20.3x
Century Aluminum CompanyCENX$6.6B157.3x8.2x5.2%49.1x
Celanese CorporationCE$5.9B-5.1x1.5x-28.8%65.9x
Warrior Met Coal, Inc.HCC$5.6B98.1x2.6x2.7%22.0x
Sensient Technologies CorporationSXT$4.8B35.7x4.0x11.3%20.4x
Materion CorporationMTRN$4.7B63.2x5.0x7.9%29.0x
H.B. Fuller CompanyFUL$3.3B21.6x1.6x7.6%10.0x
The Chemours CompanyCC$3.3B—13.0x-154.4%21.0x
Hawkins, Inc.HWKN$3.2B39.0x6.0x15.3%19.6x
Peer median—39.0x4.5x6.4%21.5x

Year-to-date ROI

BCPC since 1 January, against earlier years.

Historical volatility

BCPC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Balchem Corporation operating margin by fiscal year
Balchem Corporation operating margin by fiscal year
DateOperating margin
FY202215.4%
FY202317.3%
FY202419.2%
FY202520.2%
LineFY2025
Cost of revenueCost Of Revenue$666.5M
Gross profitGross Profit$370.6M
Operating expensesOperating Expense$161.3M
Research and developmentResearch And Development$18.5M
Total expensesTotal Expenses$827.8M
Pretax incomePretax Income$199.0M

Learn while you research

Academy chapters picked for Balchem Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 32.8, learn when high multiples are justified.6 min read
  3. 03 Business Cycles & StocksThese cyclical sectors win and lose in different macro phases.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →